Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study

Yue Yang,Jianhua Xu,Jian Xu,X. Li,Jian-Kang Hu,Xiangpei Li,Xiao Zhang,Dongyi He,Chunde Bao,Zhijun Li,Guochun Wang,Cristiano A. F. Zerbini,Alberto Spindler,Carol L Kannowski,Hanjun Wu,Fei Ji,Lujing Zhan,Meng-Ru Liu,Zhanguo Li

Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study

2021

Yue Yang
Jianhua Xu
Jian Xu
X. Li
Jian-Kang Hu
Xiangpei Li
Xiao Zhang
Dongyi He
Chunde Bao
Zhijun Li
Guochun Wang
Cristiano A. F. Zerbini
Alberto Spindler
Carol L Kannowski
Hanjun Wu
Fei Ji
Lujing Zhan
Meng-Ru Liu
Zhanguo Li

Introduction:To assess the effect of baricitinib on patient-reported outcomes (PROs) in patients with moderately to severely active rheumatoid arthritis (RA) who had an inadequate response to metho...

Keywords:

Placebo
Internal medicine
balance study
double blind
in patient
Methotrexate
Medicine
Rheumatoid arthritis
Baricitinib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations